Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average) (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $26.6 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 3.52% year-over-year to $26.6 million; the TTM value through Sep 2025 reached $26.6 million, up 3.52%, while the annual FY2024 figure was $19.4 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $26.6 million in Q3 2025 per CTNM's latest filing, up from $25.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $26.6 million in Q3 2025 and bottomed at $2.3 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $18.9 million, with a median of $24.5 million recorded in 2024.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 991.95% in 2025, down 3.52% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $2.3 million in 2023, then surged by 749.72% to $19.4 million in 2024, then soared by 37.63% to $26.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $26.6 million in Q3 2025, $25.9 million in Q2 2025, and $25.9 million in Q1 2025.